Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1766160 | 0.88 | LCK (0.60) | LCKFYNALDH1A1MEN1KMT2A | |
| SCHEMBL71552 | 0.87 | ALDH1A1 (0.44) | LCKFYNALDH1A1KMT2ARAB9A | |
| SCHEMBL71164 | 0.82 | ALDH1A1 (0.45) | LCKFYNALDH1A1KMT2AHTT | |
| SCHEMBL18312021 | 0.81 | LCK (0.56) | LCKFYNALDH1A1MEN1KMT2A | |
| SCHEMBL28786056 | 0.81 | LCK (0.77) | LCKFYNALDH1A1MEN1KMT2A | |
| SCHEMBL7489023 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNARAB9AMAPTHPGD | |
| SCHEMBL17700509 | 0.79 | HTT (0.55) | LCKFYNALDH1A1HTTMAPK1 | |
| SCHEMBL18700941 | 0.79 | HTT (0.55) | LCKFYNALDH1A1MEN1KMT2A | |
| SCHEMBL20134845 | 0.77 | LCK (0.45) | LCKFYNALDH1A1MEN1KMT2A | |
| SCHEMBL31314518 | 0.77 | HTT (0.62) | LCKFYNMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | LCK 771/4885FYN 754/4885ALDH1A1 1572/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | LCK 759/4885FYN 809/4885ALDH1A1 1357/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | LCK 767/4885FYN 787/4885ALDH1A1 1364/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | LCK 767/4885FYN 787/4885ALDH1A1 1364/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | LCK 759/4885FYN 809/4885ALDH1A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.